PTEN and leukemia stem cells

Advances in Biological Regulation

Volumn 56, Issue , 2014, Pages 22-29

  Fragoso, Rita ^a   Barata, João T ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Leukemia; Leukemia stem cells; Phosphatase and tensin homolog deleted on chromosome 10 (PTEN); PI3K Akt mTOR pathway; Signaling therapies

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN;

ANIMAL; CANCER STEM CELL; ENZYMOLOGY; GENETICS; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA; NEOPLASTIC STEM CELLS; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION;

EID: 84906761458     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2014.05.005     Document Type: Article

References (85)

1. Ailles L.E., Weissman I.L. Cancer stem cells in solid tumors. Curr Opin Biotechnol 2007, 18:460-466.
2. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988.
3. Ali I.U., Schriml L.M., Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. JNatl Cancer Inst 1999, 91:1922-1932.
4. Alimonti A., Carracedo A., Clohessy J.G., Trotman L.C., Nardella C., Egia A., et al. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 2010, 42:454-458.
5. Backman S.A., Stambolic V., Suzuki A., Haight J., Elia A., Pretorius J., et al. Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat Genet 2001, 29:396-403.
6. Bandapalli O.R., Zimmermann M., Kox C., Stanulla M., Schrappe M., Ludwig W.D., et al. NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia. Haematologica 2013, 98:928-936.
7. Barata J.T. The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival. Adv Enzyme Regul 2011, 51:37-49.
8. Berger A.H., Knudson A.G., Pandolfi P.P. Acontinuum model for tumour suppression. Nature 2011, 476:163-169.
9. Bleau A.M., Hambardzumyan D., Ozawa T., Fomchenko E.I., Huse J.T., Brennan C.W., et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009, 4:226-235.
10. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
11. Brown V.I., Fang J., Alcorn K., Barr R., Kim J.M., Wasserman R., et al. Rapamycin is active against B-precursor leukemia invitro and invivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA 2003, 100:15113-15118.
12. Castor A., Nilsson L., Astrand-Grundstrom I., Buitenhuis M., Ramirez C., Anderson K., et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 2005, 11:630-637.
13. Chalhoub N., Baker S.J. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 2009, 4:127-150.
14. Chiarini F., Grimaldi C., Ricci F., Tazzari P.L., Evangelisti C., Ognibene A., et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 2010, 70:8097-8107.
15. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006, 66:9339-9344.
16. Correia N.C., Girio A., Antunes I., Martins L.R., Barata J.T. The multiple layers of non-genetic regulation of PTEN tumour suppressor activity. Eur J Cancer 2014, 50:216-225.
17. Cox C.V., Martin H.M., Kearns P.R., Virgo P., Evely R.S., Blair A. Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. Blood 2007, 109:674-682.
18. Di Cristofano A., Pesce B., Cordon-Cardo C., Pandolfi P.P. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998, 19:348-355.
19. Evangelisti C., Ricci F., Tazzari P., Chiarini F., Battistelli M., Falcieri E., et al. Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. JCell Physiol 2011, 226:822-831.
20. Evangelisti C., Ricci F., Tazzari P., Tabellini G., Battistelli M., Falcieri E., et al. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 2011, 25:781-791.
21. Gomes A.M., Soares M.V., Ribeiro P., Caldas J., Povoa V., Martins L.R., et al. Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels. Haematologica 2014, 99:1062-1068.
22. Groszer M., Erickson R., Scripture-Adams D.D., Dougherty J.D., Le Belle J., Zack J.A., et al. PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci USA 2006, 103:111-116.
23. Groszer M., Erickson R., Scripture-Adams D.D., Lesche R., Trumpp A., Zack J.A., et al. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene invivo. Science 2001, 294:2186-2189.
24. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
25. Guo W., Lasky J.L., Chang C.J., Mosessian S., Lewis X., Xiao Y., et al. Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature 2008, 453:529-533.
26. Guo W., Schubbert S., Chen J.Y., Valamehr B., Mosessian S., Shi H., et al. Suppression of leukemia development caused by PTEN loss. Proc Natl Acad Sci USA 2011, 108:1409-1414.
27. Gutierrez A., Sanda T., Grebliunaite R., Carracedo A., Salmena L., Ahn Y., et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 2009, 114:647-650.
28. Hirschmann-Jax C., Foster A.E., Wulf G.G., Nuchtern J.G., Jax T.W., Gobel U., et al. Adistinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004, 101:14228-14233.
29. Hope K.J., Jin L., Dick J.E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004, 5:738-743.
30. Huang F.F., Wu D.S., Zhang L., Yu Y.H., Yuan X.Y., Li W.J., et al. Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia. Cancer Lett 2013, 336:96-105.
31. Huang F.F., Zhang L., Wu D.S., Yuan X.Y., Chen F.P., Zeng H., et al. PTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemia. PLoS ONE 2014, 9:e88298.
32. Huntly B.J., Gilliland D.G. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 2005, 5:311-321.
33. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell biol 2002, 4:648-657.
34. Jamieson C.H., Ailles L.E., Dylla S.J., Muijtjens M., Jones C., Zehnder J.L., et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N.Engl J Med 2004, 351:657-667.
35. Jotta P.Y., Ganazza M.A., Silva A., Viana M.B., da Silva M.J., Zambaldi L.J., et al. Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia 2010, 24:239-242.
36. Kalaitzidis D., Sykes S.M., Wang Z., Punt N., Tang Y., Ragu C., et al. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell 2012, 11:429-439.
37. Kwon C.H., Zhu X., Zhang J., Knoop L.L., Tharp R., Smeyne R.J., et al. Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat Genet 2001, 29:404-411.
38. Larson Gedman A., Chen Q., Kugel Desmoulin S., Ge Y., LaFiura K., Haska C.L., et al. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia 2009, 23:1417-1425.
39. Lee J.Y., Nakada D., Yilmaz O.H., Tothova Z., Joseph N.M., Lim M.S., et al. mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. Cell Stem Cell 2010, 7:593-605.
40. Li D.M., Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997, 57:2124-2129.
41. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
42. Luo J., Manning B.D., Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003, 4:257-262.
43. Maehama T., Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. JBiol Chem 1998, 273:13375-13378.
44. Magee J.A., Ikenoue T., Nakada D., Lee J.Y., Guan K.L., Morrison S.J. Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell 2012, 11:415-428.
45. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
46. Martelli A.M., Lonetti A., Buontempo F., Ricci F., Tazzari P.L., Evangelisti C., et al. Targeting Signaling Pathways in T-cell acute lymphoblastic leukemia initiating cells. Adv Biol Regul 2014, 10.1016/j.jbior.2014.04.004.
47. Martelli A.M., Tabellini G., Ricci F., Evangelisti C., Chiarini F., Bortul R., et al. PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy. Adv Biol Regul 2012, 52:214-227.
48. Martins L.R., Lucio P., Silva M.C., Anderes K.L., Gameiro P., Silva M.G., et al. Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia. Blood 2010, 116:2724-2731.
49. Maser R.S., Choudhury B., Campbell P.J., Feng B., Wong K.K., Protopopov A., et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007, 447:966-971.
50. Mavrakis K.J., Wolfe A.L., Oricchio E., Palomero T., de Keersmaecker K., McJunkin K., et al. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol 2010, 12:372-379.
51. McCubrey J.A., Abrams S.L., Stadelman K., Chappell W.H., Lahair M., Ferland R.A., et al. Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. Adv Enzyme Regul 2010, 50:285-307.
52. McCubrey J.A., Abrams S.L., Umezawa K., Cocco L., Martelli A.M., Franklin R.A., et al. Novel approaches to target cancer initiating cells-eliminating the root of the cancer. Adv Biol Regul 2012, 52:249-264.
53. Medyouf H., Gusscott S., Wang H., Tseng J.C., Wai C., Nemirovsky O., et al. High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. JExp Med 2011, 208:1809-1822.
54. Nishida H., Yamazaki H., Yamada T., Iwata S., Dang N.H., Inukai T., et al. CD9 correlates with cancer stem cell potentials in human B-acute lymphoblastic leukemia cells. Biochem Biophys Res Commun 2009, 382:57-62.
55. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. Ahuman colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
56. Palomero T., Sulis M.L., Cortina M., Real P.J., Barnes K., Ciofani M., et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007, 13:1203-1210.
57. Passegue E., Wagner E.F., Weissman I.L. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 2004, 119:431-443.
58. Peng C., Chen Y., Yang Z., Zhang H., Osterby L., Rosmarin A.G., et al. PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood 2010, 115:626-635.
59. Podsypanina K., Ellenson L.H., Nemes A., Gu J., Tamura M., Yamada K.M., et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999, 96:1563-1568.
60. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
61. Ribeiro D., Melao A., Barata J.T. IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia. Adv Biol Regul 2013, 53:211-222.
62. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
63. Salmena L., Carracedo A., Pandolfi P.P. Tenets of PTEN tumor suppression. Cell 2008, 133:403-414.
64. Sansal I., Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. JClin Oncol Official J Am Soc Clin Oncol 2004, 22:2954-2963.
65. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22:159-168.
66. Shehata M., Schnabl S., Demirtas D., Hilgarth M., Hubmann R., Ponath E., et al. Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. Blood 2010, 116:2513-2521.
67. Silva A., Laranjeira A.B., Martins L.R., Cardoso B.A., Demengeot J., Yunes J.A., et al. IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias. Cancer Res 2011, 71:4780-4789.
68. Silva A., Yunes J.A., Cardoso B.A., Martins L.R., Jotta P.Y., Abecasis M., et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. JClin Investig 2008, 118:3762-3774.
69. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
70. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
71. Song M.S., Salmena L., Pandolfi P.P. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012, 13:283-296.
72. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998, 95:29-39.
73. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997, 15:356-362.
74. Suzuki A., de la Pompa J.L., Stambolic V., Elia A.J., Sasaki T., del Barco Barrantes I., et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol CB 1998, 8:1169-1178.
75. Teachey D.T., Grupp S.A., Brown V.I. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol 2009, 145:569-580.
76. Trinquand A., Tanguy-Schmidt A., Ben Abdelali R., Lambert J., Beldjord K., Lengline E., et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a group for research in adult acute lymphoblastic leukemia study. JClin Oncol Official J Am Soc Clin Oncol 2013, 31:4333-4342.
77. le Viseur C., Hotfilder M., Bomken S., Wilson K., Rottgers S., Schrauder A., et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell 2008, 14:47-58.
78. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501.
79. Vogt P.K., Kang S., Elsliger M.A., Gymnopoulos M. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci 2007, 32:342-349.
80. Wang J.C., Dick J.E. Cancer stem cells: lessons from leukemia. Trends Cell Biol 2005, 15:494-501.
81. Williams R.T., den Besten W., Sherr C.J. Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. Genes Dev 2007, 21:2283-2287.
82. Wulf G.G., Wang R.Y., Kuehnle I., Weidner D., Marini F., Brenner M.K., et al. Aleukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001, 98:1166-1173.
83. Yilmaz O.H., Valdez R., Theisen B.K., Guo W., Ferguson D.O., Wu H., et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006, 441:475-482.
84. Zhang J., Grindley J.C., Yin T., Jayasinghe S., He X.C., Ross J.T., et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 2006, 441:518-522.
85. Zhou S., Schuetz J.D., Bunting K.D., Colapietro A.M., Sampath J., Morris J.J., et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001, 7:1028-1034.